PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)

Bibliographic Details
Main Authors:	J. P. Sharman, W. Jurczak, C. C. Coombs, M. Hill, D. Wang, N. C. Ku, A. Guntur, S. Shahda, C. C. Leow, P. Ghia, A. R. Mato
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850308.96349.64

Internet